World Alzheimer’s Month 2024 at the UK DRI
Throughout September, we have been shining a spotlight on our brilliant research community, highlighting and celebrating the breadth of research taking place at the UK DRI.
Read more
Developing new treatments for FTD and ALS: a bumpy road to success
In this article Prof Adrian Isaacs (UK DRI at UCL) discusses his research journey, what he has learned from setbacks, the success of his project harnessing the fruit fly and why the support of the UK DRI has been invaluable to his lab’s development.
Read more
Repurposing cheap and common drugs to treat cerebral small vessel disease
Prof Joanna Wardlaw (UK DRI at Edinburgh) is setting up the first phase III trial in cerebral small vessel disease aimed at improving cognitive symptoms by repurposing two drugs.
Read more
MHRA approves lecanemab but NICE deems drug not cost effective for use on NHS
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved lecanemab for use in the UK to treat early-stage Alzheimer’s disease. However, draft guidance released simultaneously by NICE, has said that the benefits of the new drug are too small to justify the costs, and therefore has not recommended it for availability on the NHS. Here, UK DRI researchers respond to the news.
Read more
Lancet Commission report finds nearly half of dementia cases could be prevented or delayed
The Lancet Commission on dementia prevention, intervention and care, concludes that addressing 14 modifiable risk factors, starting in childhood and continuing throughout life, could prevent or delay nearly half of dementia cases. Here, UK DRI researchers respond to the new report.
Read more
Friends of CR&T: A new network to shape dementia research
The UK DRI exists to improve the lives of people affected by dementia. By involving people who have lived experience in our research, we can ensure new treatments and technologies meet the needs of those affected.
Read more
Turning breakthroughs into treatments
We have a clearly defined vision at the UK DRI to develop effective therapeutics, diagnostics and technologies for people living with dementia. Alongside building our disease knowledge over the coming years, we will also make progress in translating these discoveries into the clinic.
Translation and innovation
Our priorities as a research institute
We accelerate, innovate, deepen and broaden discovery science in dementia, with the goal of filling the huge knowledge gap in this field. We exist to bring forward the day when research benefits people living with and those at risk of dementia.
Read our science vision
Collaboration and connection
Our efforts to increase the diversity of our team, ensure inclusion and promote equality of opportunity, align with our vision for the UK DRI’s Institute culture and identity as a world-leader in dementia research.
Equity, Diversity and Inclusion
Bringing together researchers to address major scientific questions
We study a range of neurodegenerative disorders that cause dementia. Many of them share fundamental disease mechanisms and characteristics, and greater understanding gained in one can often benefit others. To ensure we capitalise on diverse expertise, approaches and perspectives, we have established cross-centre themes.
Research themes